Physician profile
Lora A Plaskon
NPI 1477500544
$13,400.95
in general payments reported to CMS, 2019-2025
10 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $126 · 2021: $85.27 · 2022: $68.45 · 2023: $140 · 2024: $34.23 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $12,436.73 | 2019-2023 | Saffron, Self-Cath, Speedicath |
| Boston Scientific Corporation | $470.49 | 2019 | |
| Astellas Pharma US INC | $163.23 | 2019 | |
| Valencia Technologies Corporation | $104.44 | 2025 | Ecoin Device Kit |
| Laborie Medical Technologies Corp. | $68.93 | 2021-2025 | |
| 180 Medical, INC. | $63.33 | 2021-2022 | |
| Abbvie INC. | $34.23 | 2024 | |
| Therapeuticsmd, INC. | $22.79 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $20.39 | 2022 | |
| Dentsply Ih INC. | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Plaskon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.